Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanHKSE:02268 +1.86%50 ROE % is 16.25% as of Dec. 2025, which is 7% below its 10-year median of 17.39. GuruFocus rates HKSE:02268 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 199 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 85.43% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. WuXi XDC Cayman's annualized net income for the quarter that ended in Dec. 2025 was HK$1,623 Mil. WuXi XDC Cayman's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was HK$9,992 Mil. Therefore, WuXi XDC Cayman's annualized ROE % for the quarter that ended in Dec. 2025 was 16.25%.
The historical rank and industry rank for WuXi XDC Cayman's ROE % or its related term are showing as below:
HKSE:02268'
s ROE % Range Over the Past 10 Years
Min: 7 Med: 17.39 Max: 28.57
Current: 15.97
During the past 6 years, WuXi XDC Cayman's highest ROE % was 28.57%. The lowest was 7.00%. And the median was 17.39%.
HKSE:02268's ROE % is ranked better than 85.43% of 199
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.59
vs HKSE:02268: 15.97
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
WuXi XDC Cayman ROE % Related Terms
WuXi XDC Cayman ROE % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, WuXi XDC Cayman's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's ROE % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
WuXi XDC Cayman (HKSE:02268) has a ROE % of 16.25% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 17.39. Over the past decade, WuXi XDC Cayman's ROE % has ranged from 7.00 to 28.57. According to the industry distribution chart, WuXi XDC Cayman ranks #29 out of 199 companies in the Medical Diagnostics & Research industry, placing it in the top 14.6%.
Is WuXi XDC Cayman's ROE % too high?
WuXi XDC Cayman's current ROE % of 16.25% is near median its 10-year median of 17.39. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 28.57. Based on the distribution chart, WuXi XDC Cayman ranks #29 out of 199 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #29 out of 199 companies for ROE %. This places WuXi XDC Cayman in the top 15% of its industry — outperforming the majority of peers. Historically, WuXi XDC Cayman's own ROE % has ranged from 7.00 to 28.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current ROE % is 16.25%, which is near median its own 10-year median of 17.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current ROE % of 16.25%. The current ROE % is 16.25%, which is near median its 10-year median of 17.39. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current ROE % is 16.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
